Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee College of Veterinary Medicine to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal Sodium for Canine Soft Tissue Sarcomas
June 28, 2023 07:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, June 28, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with the University of Tennessee College of...
Provectus Biopharmaceuticals Announces Stockholder Approval to Undertake Reverse Split of Outstanding Equities and Reduce Number of Authorized Equities by Same Ratio
June 26, 2023 07:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, June 26, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company’s shareholders have approved the proposals of Provectus’s Board of Directors (Board) to seek...
Provectus Biopharmaceuticals Announces Publication of Activity of Pharmaceutical-Grade Rose Bengal Sodium (RBS) Against Colistin-Resistant Gram-Negative Bacteria
April 20, 2023 08:00 ET
|
Provectus Biopharmaceuticals Inc.
Colistin is used as last-resort treatment for bacterial infectionsProvectus’ RBS effectively inhibits growth of colistin-resistant G- bacteriaRBS also possesses rapid-killing feature KNOXVILLE, TN,...
Provectus Biopharmaceuticals Releases 2023 Stockholder Letter
January 09, 2023 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that it had issued a beginning-of-the-year letter for 2023 to the Company’s stockholders, which may be found...
Provectus Biopharmaceuticals Announces Decision to Not Undertake Reverse Split of Outstanding and Authorized Equities in 2022; Expects to Seek Same Stockholder Approval Again in 2023
December 12, 2022 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company’s Board of Directors (Board) has decided to not undertake the reverse stock split and...
Provectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10® and Keytruda® for First-Line Stage III Melanoma at Melanoma Bridge 2022
December 01, 2022 07:00 ET
|
Provectus Biopharmaceuticals Inc.
50% CR and 83% ORR by RECIST 1.1 criteriaRapid CRs achieved within 15 to 27 weeksMedian PFS not reached during 2-year treatment interval; 83% PFS rate100% OS rate for CRs; ongoing after 18 to 36...
Provectus Biopharmaceuticals Announces Acceptance of Small Molecule Cancer Immunotherapy PV-10® Stage III Melanoma Abstract at Melanoma Bridge 2022
November 10, 2022 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company’s ongoing, multi-cohort, Phase 1b/2 study of the combination therapy of cancer...
Provectus Biopharmaceuticals Announces World Health Organization Selection of “Rose Bengal Sodium” as International Nonproprietary Name for Active Pharmaceutical Ingredient
November 02, 2022 09:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO) has...
Provectus Biopharmaceuticals Expands Research Collaboration with The Rockefeller University to Investigate Clinical-Stage Immuno-Dermatology Agent PH-10 for Skin Inflammation
October 25, 2022 06:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has expanded its sponsored research program with James G. Krueger, MD, PhD, Co-director,...
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Texas Medical Branch at Galveston to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal for Wound Healing
September 29, 2022 06:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with Amina El Ayadi, PhD, Assistant...